MedTrace Logo

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

NCT04187404 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-01-30

Study results available
· View outcomes & findings →

Summary

This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Conditions

  • Adrenocortical Carcinoma
  • Pheochromocytoma
  • Paraganglioma

Interventions

BIOLOGICAL

EO2401

Multiple dose of EO2401

BIOLOGICAL

Nivolumab

Multiple dose of nivolumab

Sponsors & Collaborators

  • Enterome

    lead INDUSTRY

Principal Investigators

  • Jean-Michel Paillarse · Enterome

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-23
Primary Completion
2024-10-02
Completion
2024-10-02
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04187404 on ClinicalTrials.gov